(Date:12/16/2009)... 8 percent of children are uninsured, government report finds ... first six months of this year, 45.4 million Americans ... population -- had no health insurance, according to new ... addition, 58.4 million (19.4 percent) people of all ages ... year prior to the interview, and 31.9 million (10.6 ...
(Date:12/16/2009)... A new software program developed by CareRise ... facilities to calculate their staffing needs as it relates ... allows inpatient healthcare facilities to calculate their mandatory nurse-to-patient ... and receive a daily report as to how it ... leader in risk management in the healthcare industry, has ...
(Date:12/16/2009)... a 1st century shrouded man found in a tomb on ... the earliest proven case of leprosy. Details of the research ... Journal. , The molecular investigation was undertaken by Prof. ... F. Kuvin Center for the Study of Infectious and Tropical ... and Ms. Kim Vernon of Lakehead University, Canada, Prof. Azriel ...
(Date:12/16/2009)... Fortune 1000 employers strongly indicates that wellness programs have a ... , ... Minneapolis, MN (PRWEB) December 16, ... that 78 percent of employers have improved employee participation in ... In the survey, conducted by Hallmark Insights, a leader ...
(Date:12/16/2009)... Dec. 16 For ages, people from around ... therapeutic properties. Its soothing waters have a reputation that ... its involvement with miracles. Now, with the introduction of ... bathers can enjoy the legendary benefits of Dead Sea ... salt lines contain all-natural Dead Sea salt and essential ...
Breaking Medicine News(10 mins):Health News:Over 45 Million Americans Now Lack Health Insurance 2Health News:United States Patent Office Allows CareRise Patent on 24/7 Staff-Census Software 2Health News:DNA of Jesus-era shrouded man in Jerusalem reveals earliest case of leprosy 2Health News:DNA of Jesus-era shrouded man in Jerusalem reveals earliest case of leprosy 3Health News:Hallmark Insights' Employer Survey Reveals Cost-Savings Benefits of Health & Wellness Programs 2Health News:SaltWorks Launches Two All-Natural Bath Salt Lines Featuring Therapeutic Salt from the Dead Sea 2Health News:SaltWorks Launches Two All-Natural Bath Salt Lines Featuring Therapeutic Salt from the Dead Sea 3... Therapy Association (ASCTA) is formed in response to the Food and ... in everyone,s body are drugs, a position the ASCTA opposes. ... to bring adult stem cell therapy to their patients more quickly. ... ...
... NATICK, Mass., March 26 Boston Scientific Corporation (NYSE: ... the Company,s major events and news announcements at the ... Cardiology / i2 Summit, which runs from March 28-31 ... additional analyses of one-year data from the landmark SYNTAX ...
... GPO Customer HospitalsBETHEL, Conn., March 26 MedClean ... of innovative technology and services for onsite treatment ... announced that its RMW solutions, including its flagship ... by MedAssets Supply Chain Systems, a leading group ...
... March 26 It was on a train ride with a ... Cardille began her painful journey on the road to recovering from ... out of the blue if Lori thought his father was a ... face her past, and part of her healing process included writing ...
... Serve As Benchmark to Measure Upcoming Healthcare Reform ... expected during newly elected President Obama,s term, results ... Tri-State Area Employee Benefit Survey could prove to ... healthcare reform legislation can be measured.The survey was ...
... Cost-Effective OptionFORT COLLINS, Colo., March 26 Food ... builds immunity to food allergens from the comfort ... gently builds tolerance to targeted foods. The Allertherapy(TM) ... It quickly builds immunity to allergens and maintains ...
Other Medicine News:Health News:Physician Group Opposes FDA's Position on Adult Stem Cells 2Health News:Physician Group Opposes FDA's Position on Adult Stem Cells 3Health News:Boston Scientific Announces Schedule For ACC 2009 2Health News:Boston Scientific Announces Schedule For ACC 2009 3Health News:Boston Scientific Announces Schedule For ACC 2009 4Health News:Boston Scientific Announces Schedule For ACC 2009 5Health News:Boston Scientific Announces Schedule For ACC 2009 6Health News:MedClean Technologies, Inc. Awarded MedAssets Supply Chain Systems Contract 2Health News:MedClean Technologies, Inc. Awarded MedAssets Supply Chain Systems Contract 3Health News:'I'm Gonna Tell ... an offbeat tale of survival' 2Health News:Cowden Associates Releases Eighth-Annual Employee Benefit Survey Results 2Health News:Cowden Associates Releases Eighth-Annual Employee Benefit Survey Results 3Health News:New OTC Allergy Treatment Available to Food Allergy Sufferers 2(Date:12/16/2009)... MOUNTAIN VIEW, Calif., Dec. 16 ChemoCentryx, ... patients in a Phase 2 clinical trial of ... to specifically target the CCR1 chemokine receptor for ... CCX354 is a highly potent and selective antagonist ... recruitment of immune cells, such as monocytes and ...
(Date:12/16/2009)... , - MIVI-TRUST ... Total of Over,640 patients Ahead of Schedule ... (Euronext Brussels: THR), a biopharmaceutical company,focused on ... for eye,disease, vascular disease and cancer, announces ... the second Phase III trial evaluating microplasmin ...
(Date:12/15/2009)... DIEGO, Dec. 15 Volcano Corporation (Nasdaq: ... intravascular therapy guidance tools - including Fractional Flow ... and Optical Coherence Tomography (OCT) - designed to ... peripheral vascular disease, announced today the placement of ... s5 family of consoles was first launched in ...
Breaking Medicine Technology:ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 2ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 3ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 4ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 5ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 2ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 3ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 4Volcano Announces Installed Base Growth Milestone 2Volcano Announces Installed Base Growth Milestone 3Volcano Announces Installed Base Growth Milestone 4Volcano Announces Installed Base Growth Milestone 5Lumension Webinar to Discuss Key Steps to Harmonize Compliance Controls and Streamline IT Audit Processes with the Unified Compliance Framework 59722 1Lumension Webinar to Discuss Key Steps to Harmonize Compliance Controls and Streamline IT Audit Processes with the Unified Compliance Framework 59722 2Lumension Webinar to Discuss Key Steps to Harmonize Compliance Controls and Streamline IT Audit Processes with the Unified Compliance Framework 59722 3Lumension Webinar to Discuss Key Steps to Harmonize Compliance Controls and Streamline IT Audit Processes with the Unified Compliance Framework 59722 4SourceMedical Launches New Tool to Automate Insurance Eligibility Verification for Ambulatory Surgery Centers 59718 1SourceMedical Launches New Tool to Automate Insurance Eligibility Verification for Ambulatory Surgery Centers 59718 2SourceMedical Launches New Tool to Automate Insurance Eligibility Verification for Ambulatory Surgery Centers 59718 3Athens Consulting Volunteers Time To Habitat For Humanity 59714 1Athens Consulting Volunteers Time To Habitat For Humanity 59714 2... Novel Heat Shock Protein 90 Inhibitor,Reveal Further ... CAMBRIDGE, Mass. and GAITHERSBURG, Md., June 5, ... and,MedImmune, Inc. (Nasdaq:MEDI) today announced updated interim,results ... the companies' heat shock,protein 90 (Hsp90) inhibitor, ...
... Study Results Show Antibodies Against Cancer-Causing Virus,Types 16 ... Greater Than Natural,Infection Levels, CHICAGO, June 05, 2007 ... 18 months after the first of a three-dose ... vaccinated with the GlaxoSmithKline,(GSK) cervical cancer candidate vaccine ...
Other Medicine Technology:Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 2Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 3Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 4Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 5Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 6Infinity and MedImmune Present Updated Phase I Results of IPI-504,in GIST at ASCO Annual Meeting 7Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides,Sustained Immune Response in 100 Percent of Women up to 55 Years of,Age 2Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides,Sustained Immune Response in 100 Percent of Women up to 55 Years of,Age 3Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides,Sustained Immune Response in 100 Percent of Women up to 55 Years of,Age 4Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides,Sustained Immune Response in 100 Percent of Women up to 55 Years of,Age 5... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products:Biology NavigationMedical Navigation